You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

~ Buy the SEGLENTIS (celecoxib; tramadol hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

SEGLENTIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Seglentis patents expire, and when can generic versions of Seglentis launch?

Seglentis is a drug marketed by Kowa Pharms and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and five patent family members in thirty-five countries.

The generic ingredient in SEGLENTIS is celecoxib; tramadol hydrochloride. There are twenty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the celecoxib; tramadol hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Seglentis

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 19, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for SEGLENTIS
International Patents:105
US Patents:7
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for SEGLENTIS
What excipients (inactive ingredients) are in SEGLENTIS?SEGLENTIS excipients list
DailyMed Link:SEGLENTIS at DailyMed
Drug patent expirations by year for SEGLENTIS
Drug Prices for SEGLENTIS

See drug prices for SEGLENTIS

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SEGLENTIS
Generic Entry Date for SEGLENTIS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SEGLENTIS

SEGLENTIS is protected by seven US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEGLENTIS is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SEGLENTIS

Co-crystals of tramadol and coxibis
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical compositions of co-crystals of tramadol and coxibs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting SEGLENTIS

NEW PRODUCT
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride TABLET;ORAL 213426-001 Oct 15, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride TABLET;ORAL 213426-001 Oct 15, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride TABLET;ORAL 213426-001 Oct 15, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SEGLENTIS

When does loss-of-exclusivity occur for SEGLENTIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 9008
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 09304235
Estimated Expiration: ⤷  Try a Trial

Patent: 10306168
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0920358
Estimated Expiration: ⤷  Try a Trial

Patent: 2012005011
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 37754
Estimated Expiration: ⤷  Try a Trial

Patent: 71665
Estimated Expiration: ⤷  Try a Trial

China

Patent: 2186465
Estimated Expiration: ⤷  Try a Trial

Patent: 2573825
Estimated Expiration: ⤷  Try a Trial

Patent: 4817501
Estimated Expiration: ⤷  Try a Trial

Patent: 4844513
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 11248
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0130316
Estimated Expiration: ⤷  Try a Trial

Patent: 0161526
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 13956
Estimated Expiration: ⤷  Try a Trial

Patent: 18374
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 49238
Estimated Expiration: ⤷  Try a Trial

Patent: 88169
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 12011734
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 77215
Estimated Expiration: ⤷  Try a Trial

Patent: 49238
Estimated Expiration: ⤷  Try a Trial

Patent: 88169
Estimated Expiration: ⤷  Try a Trial

Patent: 86432
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 73380
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 30976
Estimated Expiration: ⤷  Try a Trial

India

Patent: 35DEN2012
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 1785
Estimated Expiration: ⤷  Try a Trial

Patent: 8256
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 99564
Estimated Expiration: ⤷  Try a Trial

Patent: 45830
Estimated Expiration: ⤷  Try a Trial

Patent: 12505847
Estimated Expiration: ⤷  Try a Trial

Patent: 13507402
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 49238
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 6285
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 6318
Estimated Expiration: ⤷  Try a Trial

Patent: 11003612
Estimated Expiration: ⤷  Try a Trial

Patent: 12003050
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 742
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 1873
Estimated Expiration: ⤷  Try a Trial

Patent: 8353
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 49238
Estimated Expiration: ⤷  Try a Trial

Patent: 88169
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 49238
Estimated Expiration: ⤷  Try a Trial

Patent: 88169
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 47830
Estimated Expiration: ⤷  Try a Trial

Patent: 99717
Estimated Expiration: ⤷  Try a Trial

Patent: 11119608
Estimated Expiration: ⤷  Try a Trial

Patent: 12120088
Estimated Expiration: ⤷  Try a Trial

San Marino

Patent: 01300048
Estimated Expiration: ⤷  Try a Trial

Patent: 01600439
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 8835
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 49238
Estimated Expiration: ⤷  Try a Trial

Patent: 88169
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1102762
Estimated Expiration: ⤷  Try a Trial

Patent: 1201892
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1471585
Estimated Expiration: ⤷  Try a Trial

Patent: 1679400
Estimated Expiration: ⤷  Try a Trial

Patent: 110069860
Estimated Expiration: ⤷  Try a Trial

Patent: 120099212
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 02112
Estimated Expiration: ⤷  Try a Trial

Patent: 03962
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 41630
Estimated Expiration: ⤷  Try a Trial

Patent: 1116273
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 12000075
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 9534
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SEGLENTIS around the world.

Country Patent Number Title Estimated Expiration
South Korea 20120099212 CO-CRYSTALS OF TRAMADOL AND COXIBS ⤷  Try a Trial
Mexico 2012014087 COMPOSICIONES FARMACEUTICAS DE CO- CRISTALES DE TRAMADOL Y COXIBS. (PHARMACEUTICAL COMPOSITIONS OF CO-CRYSTALS OF TRAMADOL AND COXIBS.) ⤷  Try a Trial
European Patent Office 2488169 CO-CRISTAUX DE TRAMADOL ET NSAID (CO-CRYSTALS OF TRAMADOL AND COXIBS) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SEGLENTIS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0731795 10075033 Germany ⤷  Try a Trial PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.